Appendix A.

Figure S1-1. Comparative Fourier transform infrared (FTIR) between CT-P13 and INX.
CT-P13 and INX were analysed in a FTIR spectrometer and spectral data was plotted as a function of % transmission. CT-P13 A, B and C represent three different batches of CT-P13 drug.
Figure S1-2. Comparative TNFα neutralizing assay between CT-P13 and INX

CT-P13 compounds and INX were used in a TNFα neutralising assay. The EC\textsubscript{50} values of CT-P13 and INX were compared with the reference standard EC\textsubscript{50}. *Relative neutralizing potency (%) of drug was calculated as a percentage of the reference standard EC\textsubscript{50}. The bold line indicates the average value for INX drug in this assay. CT-P13 A, B and C represent three different campaign batches of CT-P13 drug substance.
Figure S1-3. Comparative complement dependent cytotoxicity (CDC) between CT-P13 and INX

CT-P13 and INX were used in a CDC assay. *The relative CDC bioactivities of CT-P13 and INX were calculated as a percentage of the EC$_{50}$ of each sample curve Vs the EC$_{50}$ of the reference standard curve. Error bars represent standard deviation of each sample analysed in duplicate. The bold line indicates the average value for INX drug in this assay.